関連する実験動画
Updated: Dec 11, 2025

06:09
Assaying the Kinase Activity of LRRK2 in vitro
Published on: January 18, 2012
22.9K
パーキンソン病におけるLRRK2の構造と微小管の相互作用モデル
C K Deniston1,2, J Salogiannis1,3, S Mathea4
1Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.
Nature
|August 20, 2020
まとめ
レウシンに富んだリピートキナーゼ2 (LRRK2) フィラメントは,マイクロチューブル上のモータータンパク質の動きを阻害する. 開かれたLRRK2構造を安定させる阻害剤は,フィラメント形成を減少させ,パーキンソン病の治療戦略を提供します.
科学分野:
- 神経科学
- 構造生物学
- 分子生物学
背景:
- レウシンに富んだリピートキナーゼ2 (LRRK2) は,パーキンソン病の病原性における重要な遺伝子である.
- 膜輸送と微小管結合におけるLRRK2の役割が確立された.
- 構造的なデータが限られているため,LRRK2の機能の理解が困難です.
研究 の 目的:
- LRRK2の触媒半分の構造を決定する.
- マイクロチューブルに関連したLRRK2をモデル化する.
- LRRK2-マイクロチューブル相互作用のメカニズムとキナーゼ構成によるその調節を解明する.
主な方法:
- 構造の決定のためにX線結晶学または冷凍-EM.
- インサイト構造モデリングのための冷凍電子トモグラフィー
- 浄化されたモーターとLRRK2を用いた in vitro 運動性測定
- LRRK2フィラメント形成と阻害効果を評価するための細胞ベースの測定法.
主要な成果:
- LRRK2の触媒半分の構造を報告した.
- マイクロチューブル関連LRRK2の原子モデルを開発した.
- LRRK2フィラメントがキネシン-1とダイネイン-1の運動性を阻害することが示された.
- 開かれた形状を安定させるキナーゼ阻害剤は,細胞内のLRRK2フィラメント形成を減少させることが示された.
結論:
- LRRK2の構成は,その微小管の結合とオリゴメリゼーションを調節する.
- LRRK2は,マイクロチューブルベースのモーターの物理的な障害物として機能することができます.
- LRRK2構成を標的とした治療戦略は,パーキンソン病に有益である.
関連する概念動画
Lysosomal Hydrolases
4.3K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.3K
Assembly of Complex Microtubule Structures
2.3K
Complex microtubule structures are present in resting cells and in dividing cells. In resting cells, they are responsible for maintaining the cellular architecture, tracks for intracellular transport, positioning of organelles, assembly of cilia and flagella. They mediate the bipolar spindle assembly for chromosomal segregation and positioning of the cell division plate in dividing cells. The formation of microtubule complex structures depends on the cell type, cell stage, and cell function.
2.3K
Microtubule Formation
7.2K
Microtubules are dynamic structures that undergo continuous assembly and disassembly. They originate from specialized multi-protein complexes known as microtubule organizing centers or MTOCs. Within the MTOC, the point of origin of the microtubule is known as the minus end, while the end radiating outward is the plus end. Microtubules serve two primary functions — the organization of spindle complexes to separate sister chromatids during mitotic or meiotic cell division and the formation...
7.2K
Microtubule Associated Proteins (MAPs)
5.6K
Microtubule function and architecture are regulated by an array of specialized proteins called microtubule-associated proteins or MAPs. These proteins are widespread across different organisms and have conserved protein motifs, like the multi-TOG domain for tubulin binding found in the CLASP family of MAPs. Some MAPs are lineage-specific based on their conserved domains. Their functions depend upon the cytoskeletal architecture and cell type they are located within. In-plant cells, a specific...
5.6K
Destabilization of Microtubules
3.3K
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
3.3K
Parkinson's Disease: Overview
1.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.5K

